Eye diseases such as cataracts and glaucoma are major causes of visual impairment and blindness worldwide. Cataracts, which involve the clouding of the eye’s natural lens, and glaucoma, a group of eye conditions that damage the optic nerve, are both progressive and debilitating conditions. Cataracts are primarily linked to aging and involve the gradual breakdown of lens proteins, while glaucoma is often associated with increased intraocular pressure (IOP) that damages the optic nerve fibers. Both conditions can significantly reduce quality of life, and while traditional treatments exist, new therapeutic options are being explored. One promising avenue is the use of protein peptides, which have shown potential in protecting the eyes, enhancing healing, and even preventing or slowing the progression of cataracts and glaucoma.
